Hardy Reed’s Novo Nordisk NVO Stock Holding History

Hardy Reed’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$275K	Buy	7,261 +2,715	+60%	+$125K	0.02%	212
2026 Q2	$218K	Buy	+4,546	New	+$195K	0.01%	241
2026 Q1	–	Sell	-7,177	Closed	-$365K	–	253
2025 Q4	$365K	Buy	7,177 +90	+1%	+$4.6K	0.03%	176
2025 Q3	$393K	Sell	7,087 -1,445	-17%	-$84.6K	0.03%	165
2025 Q2	$589K	Buy	8,532 +238	+3%	+$16.2K	0.05%	126
2025 Q1	$576K	Sell	8,294 -56	-0.7%	-$4.62K	0.05%	121
2024 Q4	$718K	Sell	8,350 -1	-0%	-$108	0.06%	108
2024 Q3	$994K	Buy	8,351 +2	+0%	+$267	0.09%	95
2024 Q2	$1.19M	Buy	+8,349	New	+$1.11M	0.12%	86

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Everett Harris & Co Los Angeles, California $8.46B AUM 13.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return

Markel Group Glen Allen, Virginia $12.8B AUM 8.77% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Hardy Reed's NVO Position: Q3 2026 in Review

Hardy Reed increased its Novo Nordisk (NVO) stake by 60% in Q3 2026, buying an estimated $125K and bringing the position to 7,261 shares worth $275K. The position accounts for 0.02% of the portfolio, ranked #212.

Hardy Reed first reported a position in NVO in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.19M in Q2 2024. 861 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

Hardy Reed held 7,261 shares of Novo Nordisk worth $275K as of Q3 2026.
Hardy Reed bought 2,715 Novo Nordisk shares in Q3 2026, an estimated $125K.
Novo Nordisk made up 0.02% of Hardy Reed's portfolio in Q3 2026, its #212 holding.
Hardy Reed first reported a position in Novo Nordisk in Q2 2024 and has held it in 9 quarters since.
Hardy Reed's Novo Nordisk position peaked at $1.19M in Q2 2024.
861 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Hardy Reed's 13F filing for Q3 2026, filed 6 Nov 2026.